Everest Medicines is a biopharmaceutical company focused on the discovery and development of novel pharmaceutical therapies and vaccines to meet critical unmet medical needs in Greater China and the Asia Pacific region. Their pipeline includes treatments for conditions such as IgA nephropathy and primary membranous nephropathy, aiming to improve patient outcomes through targeted therapeutic interventions.
Funding
$310M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JPFounders
Product
Problem
Patients in Greater China and the Asia Pacific region face critical unmet medical needs due to limited access to innovative pharmaceutical therapies and vaccines. This gap hinders effective treatment and prevention of diseases, impacting patient outcomes and public health.
Solution
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines to address these unmet needs. The company's pipeline includes treatments for conditions such as IgA nephropathy and primary membranous nephropathy. By focusing on these underserved markets, Everest Medicines aims to improve patient outcomes through targeted therapeutic interventions and expanded access to advanced medicines.
Target Audience
The primary target audience includes patients in Greater China and the Asia Pacific region suffering from diseases with limited treatment options, as well as healthcare providers seeking innovative therapies.
Features
- Focus on novel therapies and vaccines for critical unmet medical needs.
- Pipeline includes treatments for IgA nephropathy (e.g., NEFECON®) and primary membranous nephropathy (e.g., EVER001).
- Capabilities in discovery, development, manufacturing, and commercialization.
- Targeting the Greater China and Asia Pacific markets.